Clinical Trial Update: Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B

View source ↗

Summary

This completed observational study assessed the safety of room-temperature-stable NovoSeven in patients with Haemophilia A or Haemophilia B.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilia

Drugs mentioned

• NovoSeven (recombinant coagulation factor VIIa)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Haemophilia A | Status: COMPLETED